Patient-centered innovations in ambulatory care: developing a fixed-dose tablet to enhance adherence for patients with chronic diseases.

IF 2.4 4区 医学 Q3 CHEMISTRY, MEDICINAL
Saleh F Alqifari, Hanan Alshareef, Hesham M Tawfeek, Palanisamy Amirthalingam, Sadeem F Alharbi, Rahaf M Alatawi, Hayaa T Alahmari, Khulood A Qasem, Ghareb M Soliman
{"title":"Patient-centered innovations in ambulatory care: developing a fixed-dose tablet to enhance adherence for patients with chronic diseases.","authors":"Saleh F Alqifari, Hanan Alshareef, Hesham M Tawfeek, Palanisamy Amirthalingam, Sadeem F Alharbi, Rahaf M Alatawi, Hayaa T Alahmari, Khulood A Qasem, Ghareb M Soliman","doi":"10.1080/03639045.2025.2513407","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To improve medication adherence in patients with chronic diseases by developing a tablet formulation containing a combination of metformin, atorvastatin, aspirin, and enalapril maleate. Significance: Effectively managing chronic diseases often requires multiple medications, which can result in low patient adherence and suboptimal therapeutic outcomes. Developing a combination tablet is an effective modality to address this issue.</p><p><strong>Methods: </strong>To test the patient perception, an online survey was distributed patients with chronic diseases. Based on the survey results, combination tablets were prepared by direct compression using a multifunctional excipient (PROSOLV<sup>®</sup> EASYtab). The compatibility between the drugs and excipients was studied using differential scanning calorimetry (DSC) and Fourier-transform infrared (FT-IR) spectroscopy. The tablets were evaluated for weight uniformity, friability, hardness, thickness, diameter, disintegration time, uniformity of drug content, and <i>in vitro</i> drug release.</p><p><strong>Results: </strong>Most participants reported issues with non-adherence, but expressed a strong positive perception of combination tablets, particularly regarding their effectiveness in improving their condition. DSC and FT-IR studies confirmed the compatibility of the investigated drugs with each other and the used excipient. The tablets fulfilled the European Pharmacopeia 2014 specifications for the tested parameters. The release of all four drugs was fast and a cumulative percent drug release of approximately 50-85% was observed after 15 min.</p><p><strong>Conclusions: </strong>These findings highlight the significant potential of the combination tablets as a single-dose delivery system, allowing the simultaneous administration of multiple medications for patients with chronic diseases, thereby enabling more effective and streamlined management.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"826-835"},"PeriodicalIF":2.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development and Industrial Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03639045.2025.2513407","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To improve medication adherence in patients with chronic diseases by developing a tablet formulation containing a combination of metformin, atorvastatin, aspirin, and enalapril maleate. Significance: Effectively managing chronic diseases often requires multiple medications, which can result in low patient adherence and suboptimal therapeutic outcomes. Developing a combination tablet is an effective modality to address this issue.

Methods: To test the patient perception, an online survey was distributed patients with chronic diseases. Based on the survey results, combination tablets were prepared by direct compression using a multifunctional excipient (PROSOLV® EASYtab). The compatibility between the drugs and excipients was studied using differential scanning calorimetry (DSC) and Fourier-transform infrared (FT-IR) spectroscopy. The tablets were evaluated for weight uniformity, friability, hardness, thickness, diameter, disintegration time, uniformity of drug content, and in vitro drug release.

Results: Most participants reported issues with non-adherence, but expressed a strong positive perception of combination tablets, particularly regarding their effectiveness in improving their condition. DSC and FT-IR studies confirmed the compatibility of the investigated drugs with each other and the used excipient. The tablets fulfilled the European Pharmacopeia 2014 specifications for the tested parameters. The release of all four drugs was fast and a cumulative percent drug release of approximately 50-85% was observed after 15 min.

Conclusions: These findings highlight the significant potential of the combination tablets as a single-dose delivery system, allowing the simultaneous administration of multiple medications for patients with chronic diseases, thereby enabling more effective and streamlined management.

以患者为中心的门诊护理创新:开发一种固定剂量片剂以增强慢性病患者的依从性。
目的研制二甲双胍、阿托伐他汀、阿司匹林和马来酸依那普利联合用药的片剂,提高慢性病患者的药物依从性。有效治疗慢性疾病通常需要多种药物,这可能导致患者依从性低和治疗效果欠佳。开发联合片剂是解决这一问题的有效途径。方法对慢性疾病患者进行在线调查,以检验患者的认知。根据调查结果,采用多功能赋形剂(PROSOLV®EASYtab)直接压缩制备联合片剂。采用差示扫描量热法(DSC)和傅里叶变换红外光谱(FT-IR)研究了药物与辅料的配伍性。考察其重量均匀性、脆性、硬度、厚度、直径、崩解时间、药物含量均匀性和体外释放度。结果大多数参与者报告了不依从性问题,但对联合片剂表达了强烈的积极看法,特别是关于其改善病情的有效性。DSC和FT-IR研究证实了所研究药物之间以及所用赋形剂之间的相容性。所述片剂符合欧洲药典2014年所测试参数的标准。所有四种药物的释放速度都很快,在15分钟后观察到药物的累积释放率约为50-85%。这些发现突出了联合片剂作为单剂量给药系统的巨大潜力,允许多种药物同时给药慢性疾病患者,从而实现更有效和简化的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.80
自引率
0.00%
发文量
82
审稿时长
4.5 months
期刊介绍: The aim of Drug Development and Industrial Pharmacy is to publish novel, original, peer-reviewed research manuscripts within relevant topics and research methods related to pharmaceutical research and development, and industrial pharmacy. Research papers must be hypothesis driven and emphasize innovative breakthrough topics in pharmaceutics and drug delivery. The journal will also consider timely critical review papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信